other

Updated:

GeneScience Pharmaceuticals Co.

GeneScience Pharmaceuticals Co., also known as Changchun GeneScience Pharmaceuticals Co., Ltd., develops drugs. It operates a technology platform with global...

GeneScience Pharmaceuticals Co.

GeneScience Pharmaceuticals Co., also known as Changchun GeneScience Pharmaceuticals Co., Ltd., develops drugs. It operates a technology platform with global reach and maintains a research and development pipeline. Progress has occurred in endocrine metabolism, women's health, and oncology.

General information

Firm type

other

Year founded

1997

Location

Region

Asia

Country

China

City

Changchun

Corporate office

Changchun, China

Additional offices

Shanghai · Mountain View · Basingstoke · Shenzhen · San Francisco · Basel · London · Taipei

Principals

unspecified

总经理, 首席科学家

Sector focus

Healthcare ServicesBiotechPharmaceuticals

Frequently asked questions

Who runs investment decisions at GeneScience Pharmaceuticals?

The firm’s chief scientist — who also serves as general manager and holds a PhD from the University of California — leads both R&D and corporate strategy. The board is ultimately controlled by state-owned Changchun High-Tech (SZ000661).

How does GeneScience source proprietary drug development?

GeneScience uses AI-driven molecular design and four core technology platforms: AI, precision targeting, multifunctional molecules, and long-acting formulations. It also in-licenses foreign assets and out-licenses its own molecules globally, as demonstrated by the 2025 Yarrow deal.

Is GeneScience structured as a family office?

No. GeneScience is a state-controlled pharmaceutical subsidiary with shares publicly traded via parent Changchun High-Tech. It does not operate as a wealth management or investment vehicle for any family.

What investment stages does GeneScience typically target?

GeneScience focuses on preclinical through Phase III clinical development. It has 40-plus assets in clinical phases and over 35 Class 1 new drugs. It also commercializes approved drugs across 40-plus countries.

Which sectors does GeneScience explicitly avoid?

The firm does not publicly disclose excluded sectors. Its stated focus is endocrinology, oncology, women’s health, immunology, and rare diseases.

How is GeneScience related to Changchun High-Tech?

GeneScience is a controlled subsidiary of Changchun High-Tech (stock code SZ000661), a state-owned enterprise listed on the Shenzhen Stock Exchange. Changchun High-Tech consolidates GeneScience’s financial results.

Does GeneScience maintain philanthropic structures?

Yes. GeneScience has received the China Red Cross Society’s Special Contribution Award and was named a "Charity Model" by the China Charity List. However, the firm does not separately disclose a dedicated foundation.

Profile maintained by using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.

Need institutional-grade insight on investors?

Altss delivers:

Principals with verified direct contactsAllocation history by asset classOSINT-derived deal signals
Book a demo

Prefer a guided tour?

We’ll walk you through:

Interactive funding timelinesCustom mandate & allocation filters
Book a demo

More Changchun other profiles